A dedicated team of veterans with deep experience in the pharmaceutical and medical device industries provide day-to-day leadership in advancing Microbiota Restoration Therapy™ drug platform at Rebiotix.
Lee Jones is the founder, president, and chief executive officer of Rebiotix, a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.
Lee has over 30 years of experience as a medical technology executive and entrepreneur in large and small companies and academia. With Rebiotix as her first foray into biotechnology, Lee is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT). The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection.
Before joining Rebiotix, Lee was the chief administrative officer of the Schulze Diabetes Institute at the University of Minnesota. She is also the former president and chief executive officer of Inlet Medical, a privately held medical device company that she grew to profitability prior to its sale to CooperSurgical in 2006. Prior to Inlet, she spent 14 years at Medtronic where she developed and commercialized several innovative products, including InterStim – a surgically implanted neurostimulation device for urinary incontinence that opened up new markets for the company.
Lee has served on several public and private boards and is currently on the board of Electromed Inc., on the University of Minnesota’s Office of Technology Commercialization advisory board, and on the board of Medical Alley Association, an industry association. She is a member of the Sofia Angel Investment Fund and is an advisor to several small companies.
Ms. Jones has a BS in Chemical Engineering from the University of Minnesota and an Executive Management degree from the Carlson School of Management at the University of Minnesota.
Dale N. Gerding, MD, MACP, FIDSA, FSHEA, joined Rebiotix in the newly created position of Chief Medical Officer in May 2015. Dr. Gerding brings to Rebiotix a broad background in epidemiology and expertise in the research and treatment of Clostridium difficile (C. diff.) disease. In this role Dr. Gerding will help guide the Company’s Clinical programs and strategies in the treatment of C. diff. infection.
Currently, Dr. Gerding is a Professor of Medicine in the Division of Infectious Diseases at Loyola University Chicago Stritch School of Medicine, Maywood, IL and Research Physician at the Hines, Veterans Affairs Hospital, Hines, IL.
Dr. Gerding’s long and distinguished career includes past president of the Society for Healthcare Epidemiology of America, past chair of the antibiotic resistance committee of SHEA and past chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA. He was the recipient of the 2013 William S. Middleton Award. The Middleton Award is the highest honor awarded annually by the Biomedical Laboratory Research and Development Service to senior VA biomedical research scientists. In addition, he has been a Merit Review funded research investigator in the US Department of Veterans Affairs for over 35 years.
In addition to authoring of over 350 peer-reviewed journal articles, book chapters, and reviews, he is a member of the editorial boards of Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Gut Microbes, and Infection Control and Hospital Epidemiology. Most recently, he was the lead author of a major article published in the Journal of the American Medical Association on the use of a non-toxigenic strain of C. diff. for prevention of recurrent CDI and a co-author of an epidemiological study published in the New England Journal of Medicine that reported that C. diff. was responsible for almost half a million infections and was associated with approximately 29,000 deaths in the US in 2011.
Dr. Gerding received his undergraduate degree in physics from St. John’s University in Collegeville, MN, attended graduate school in physics at UCLA in Los Angeles, CA, and received his MD from the University of Minnesota Medical School, Minneapolis, MN. He completed his medical residency and infectious diseases fellowship at the University of Minnesota and Minneapolis Veteran’s Affairs Medical Center. He is board certified in internal medicine and infectious diseases and a Master of the American College of Physicians and a member of the American Society for Microbiology.
Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections.
Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Edward Burd, Ph.D., has 25 years of regulatory affairs experience working first at FDA/CBER and then in startup and established pharma companies developing products for serious, unmet medical needs based on gene therapy, biologics, specified biotech products, and neurotoxins.
Prior to joining Rebiotix, Dr. Burd served as Global Regulatory Leader (GRL) for Allergan in dermatology, facial aesthetics, and neurology. Before that, he served as Director of Global Product Strategy and Regulatory Affairs for AbbVie, where he served as GRL for the biologics and new chemical entities for investigational treatments of multiple sclerosis, neuropathic pain, rheumatoid arthritis, cystic fibrosis, Crohn’s disease, and celiac disease. Dr. Burd’s career is further highlighted by senior regulatory affairs positions at Amgen, Bayer Healthcare Pharmaceuticals and Maxygen.
Prior to his career in the biotech industry, Dr. Burd was Senior Staff Fellow at the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. Here he spent seven years as a CMC reviewer for Gene Therapy products and authored more than 20 publications. Dr. Burd received his undergraduate degree in biology from California State College, earned a Ph.D. in microbiology from Virginia Polytechnic Institute and State University, and performed post-doctoral research at Harvard Medical School, MIT, and the National Institutes of Health. He is a past fellow of the National Research Council.
Lindy Bancke, Pharm.D., joined Rebiotix in 2018 with a strong background in clinical development and strategic leadership at biotech and mid-size pharmaceutical companies. Dr. Bancke’s clinical and program leadership experience spans first-in-human studies to global Phase 3 trials, as well as products with orphan designation, fast track status, and unique regulatory pathway.
Prior to joining Rebiotix, Dr. Bancke spent 10 years at Upsher-Smith Laboratories, leading clinical trials and research strategy, as well as cross-functional development programs for both ANDA and NDA products. Most recently, she was the Clinical and Development Program Lead at Proximagen, a privately-held biotech company focused on small molecule drug discovery and development. Here, she was the lead for an early-phase neuro-oncology program, as well as working on a late-stage epilepsy product preparing for NDA submission.
Dr. Bancke received her undergraduate degree in biology from the University of Nebraska–Lincoln and earned a PharmD from the University of Nebraska Medical Center, after which she completed a post-doctoral fellowship in clinical research.
Nancy Timm is a seasoned finance manager with over 20 years of experience working with small and start-up businesses. Prior to joining Rebiotix, she held positions at the Institute for Environmental Assessment where she was CFO and at Inlet Medical among others. Inlet Medical was a privately held medical device company prior to being sold to CooperSurgical. In her career, she was also involved in the turnaround of a nearly bankrupt company, working with financial institutions, regulatory agencies and vendors in the process. Nancy’s expertise includes strategic planning, financial reporting, annual audits, internal/external sales force management and mergers and acquisitions. She specializes in initiatives to streamline processes and increase the efficiency of business systems to improve bottom line results.